Table 3.
Results from the biochemical assay after acute 1MeTIQ treatment
| Treatment | n | NA | NM | 5-HT | 5-HIAA |
|---|---|---|---|---|---|
| FCX | |||||
| Control | 5 | 265 ± 15 | 17 ± 3 | 253 ± 12 | 243 ± 5 |
| MK-801 | 5 | 307 ± 22* | 26 ± 3 | 250 ± 18 | 241 ± 11 |
| 1MeTIQ | 9 | 336 ± 11*** | 44 ± 4*** | 343 ± 11*** | 202 ± 9** |
| Olanzapine | 10 | 316 ± 7** | 20 ± 3 | 262 ± 9 | 254 ± 11 |
| 1MeTIQ + MK-801 | 6 | 341 ± 10*** | 48 ± 7***### | 333 ± 14***### | 171 ± 11***### |
| Olanzapine + MK-801 | 10 | 319 ± 9** | 22 ± 2 | 252 ± 9 | 244 ± 7 |
| F |
F(5/39) = 4.38 p < 0.01 |
F(5/37) = 12.65 p < 0.001 |
F(5/42) = 13.92 p < 0.001 |
F(5/41) = 10.40 p < 0.001 |
|
| HIP | |||||
| Control | 6 | 301 ± 20 | 24 ± 3 | 226 ± 13 | 309 ± 12 |
| MK-801 | 6 | 295 ± 16 | 25 ± 4 | 202 ± 18 | 327 ± 16 |
| 1MeTIQ | 10 | 341 ± 20 | 44 ± 4*** | 284 ± 14** | 288 ± 10 |
| Olanzapine | 9 | 289 ± 10 | 33 ± 3 | 235 ± 10 | 356 ± 9 |
| 1MeTIQ + MK-801 | 6 | 295 ± 14 | 32 ± 3 | 265 ± 10*## | 255 ± 22# |
| Olanzapine + MK-801 | 9 | 313 ± 21 | 22 ± 1 | 217 ± 8 | 302 ± 23 |
| F |
F(5/40) = 1.35 p = 0.26 |
F(5/39) = 7.07 p < 0.001 |
F(5/40) = 6.33 p < 0.001 |
F(5/40) = 3.91 p < 0.01 |
|
NA, 5-HT and their metabolites (NM, 5-HIAA) were measured in the Fcx and hippocampus using HPLC. The data were analyzed using one-way ANOVA and a post hoc Duncan’s MRT. The results are shown as the means ± SEM. N = 8–10 rats per group
*p < 0.05; **p < 0.01; ***p < 0.001 indicate significant changes compared to the control; #p < 0.05; ##p < 0.01; ###p < 0.001 indicate significant changes compared to the model (MK-801) group